Bicara Therapeutics Inc.
BCAX
Positions held
Your positionsBCAX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Bicara Therapeutics operates in the promising biotechnology sector, focusing on innovative therapies that could address unmet medical needs.
- The company's market cap stands at approximately $1.1 billion, indicating significant investor interest.
- Bicara has a strong buy recommendation with a target mean price of $35.5, suggesting potential upside.
- Bicara Therapeutics has reported zero revenue over the past several quarters, indicating challenges in generating income.
- The company has consistently posted negative net income, with a loss of $55.436 million in Q2 2026.
- Current financial metrics show a profit margin of 0.0% and a debt-to-equity ratio of 0.248, reflecting financial instability.
Fundamentals
| Market cap | $1.14B | Enterprise value | $646.05M | Trailing P/E | — | Forward P/E | -4.90 |
| PEG | — | Price / book | 2.43 | Beta | -0.69 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -41.0% | ROA | -26.1% | Debt / equity | 0.00 |
| Current ratio | 11.59 | Free cash flow | -$76.95M | Analyst recommendation | strong_buy | Mean target | $35.50 |
| 52w high | $30.99 | 52w low | $13.70 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — | — |
| Net income | -$55.4M | -$56.2M | -$37.4M | -$36.3M | -$27.4M |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$60.0M | -$60.2M | -$41.1M | -$40.7M | -$32.0M |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$138M | -$68.0M | -$52.0M | -$37.8M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$156M | -$82.4M | -$39.9M | -$37.7M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-09-30 · Pliant Therapeutics Appoints David Raben as Chief Medical Officer
2026-09-03 · Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-08-19 · Can Bicara (BCAX) Commercialize Ficera? Breakthrough 3-Year Data Faces Execution Risk in C-Suite Overhaul
2026-08-19 · BMO Capital Initiates Bicara Therapeutics at Outperform
2026-08-18 · Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript
2026-08-14 · Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2026-08-12 · Bicara Therapeutics Insider Sold Shares Worth $524,533, According to a Recent SEC Filing
2026-08-12 · Bicara Therapeutics Insider Sold Shares Worth $279,750, According to a Recent SEC Filing
2026-08-12 · Bicara Therapeutics Insider Sold Shares Worth $349,591, According to a Recent SEC Filing
2026-08-11 · Bicara Therapeutics' Cancer Study On Track for 2026 Enrollment, Wedbush Says
Price (daily)
Full chart · RSI · MACD · patterns